At least 10% of persons who contract COVID-19 suffer with prolonged symptoms. Such individuals have been called “Long Haulers.” Their symptoms are very similar to those of Chronic Fatigue Syndrome (ME/CFS). Since it is widely believed that early treatment is beneficial in ME/CFS, we are encouraging such post-COVID Long Haulers to seek care early with a specialist.
Toward that end, Hunter-Hopkins Center has just embarked on a program to treat Long Haulers with Ampligen / rintatolimod, a Toll-like Receptor 3 agonist and immumodulatory drug. This program is part of the existing AMP-511 open label clinical trial and will study the effects of Ampligen with regard to safety and activity in patients with Long Haulers. AMP-511 study details posted on ClinicalTrial.gov can be viewed HERE. The study is sponsored by AIM Immunotech, makers of Ampligen.
Prospective Long Haulers may contact Wendy Springs CCRP, our research coordinator, for more details (704 543 9692).